ClinicalTrials.gg
CompletedNCT05687526Updated Mar 9, 2026

A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus

A Phase 1 interventional study of Telitacicept in Systemic Lupus Erythematosus, sponsored by RemeGen Co., Ltd.. Completed at 12 sites in China. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by RemeGen Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing telitacicept in Lupus Erythematosus, Systemic — 6 open to participants now, 7 under way, 1 of them phase 3. telitacicept · Lupus Erythematosus, Systemic.

Enrollment
12th of 13
16 · median 64
Started
2023
with 2 others
Phase 1
2 of 13
none open now
Registered
7th of 13
by date
Lead sponsor
4 of 13
RemeGen Co., Ltd.

Among the 13 studies testing telitacicept in Lupus Erythematosus, Systemic, this one is the 12th largest by enrollment, is one of 3 that started in 2023, is one of 2 in phase 1, and was the 7th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

6 of the 13 studies testing telitacicept in Lupus Erythematosus, Systemic are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About telitacicept

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing telitacicept in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

This is a multi-center, open-label, phase 1 study.

Read the detailed description

The purpose of this study is to evaluate the pharmacokinetics (PK) of multiple doses of Telitacicept in subjects with childhood-onset systemic lupus erythematosus (cSLE) on a background of standard of care therapy and explore the safety and efficacy of Telitacicept in patients with cSLE.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • systemic lupus erythematosus
  • pediatrics
  • PK
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Fulfills SLICC 2012 or 2019 EULAR/ACR classification criteria for SLE.
  2. 5-17 years of age when signing the .
  3. Suject and/or legal guardian or parent provided written informed consent.
  4. SELENA SLEDAI score ≥ 8 at screening.
  5. Serum autoantibodies (ANA and/or anti ds-DNA) tested positive at screening.
  6. Have been on a stable standard of care for SLE for at least 30 days prior to randomization.
  7. Female patients are required to be non-pregnant, non-lactating or sterile.

Main Exclusion Criteria:

  1. Have received Telitacicept at any time.
  2. Have received any of the following therapies within 6 months of baseline: B-cell targeted treatment, e.g., belimumab, rituximab, abatacept, other biologicals.
  3. Have received any of the following therapies within 90 days of baseline: anti-TNF or anti-IL-6 therapy, interleukin-1 receptor antagonist, intravenous immunoglobulin (IVIG), plasmapheresis.
  4. Have received any of the following therapies within 30 days of baseline: Intravenous cyclophosphamide, non-biological investigational agents (within 30 days of baseline or 5 half-lives, whichever is longer), newly added /immunomodulatory agent, anti-malarial, NSAID, high-dose prednisone or equivalent (> 1.5 mg/kg/day) or any intramuscular or intravenous .
  5. Have received within 30 days of baseline.
  6. Participated in an interventional clinical trial within 6 months of screening.
  7. Active CNS lupus requiring treatment within 60 days of baseline, including seizure, psychosis, organic brain syndrome, cerebrovascular accident, cerebritis or CNS vasculitis.
  8. Currently on kidney replacement therapy (hemodialysis, peritoneal dialysis) or in need of such therapy within 90 days of baseline.
  9. \<30 mL/min/1.73m2.
  10. Acute severe nephritis.
  11. History of vital organ transplant (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant.
  12. Significant unstable or uncontrolled acute or chronic diseases (cardiovascular, lung, hematology, gastrointestinal, liver, renal, neurologic, or infectious disease) that could be explained by causes other than SLE.

13 Have planned surgery, laboratory abnormalities, other diseases or conditions that, in the opinion of the investigator, makes the subject unsuitable for the study.

14. History of malignant neoplasm in the past 5 years. 15. Primary immune deficiency. 16. Acute or chronic infections requiring treatment. 17. or positive. 18. Tuberculosis. 19./HbcAb positive. 20.HBcAb positive. 21.History of COVID-19 within 4 weeks prior to screening. 22.History of hospitalization due to severe Covid-19 within 12 months prior to screening.

23.History of allergy to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies.

24.History of drug or alcohol abuse or dependence within 364 days prior to baseline.

25.Investigators believe that there are other factors that are not suitable for participating in the experiment.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Telitacicept

    The dosing of Telitacicept frequency was based on body weight and age.

    Biological: Telitacicept

Interventions

  • BiologicalTelitacicept

    12-17 years old: Telitacicept 2.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks. 5-11years old: Telitacicept 3.0-3.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks.

    Also known as: RC18

06

What researchers measure

Primary outcomes

  1. Cmax of Telitacicept

    Cmax is defined as peak plasma concentration of Telitacicept

    Time frame: up to 42 days following the last dose of Telitacicept

  2. tmax of Telitacicept

    tmax is defined as time to reach Cmax of Telitacicept

    Time frame: up to 42 days following the last dose of Telitacicept

  3. Ctrough of Telitacicept

    Ctrough is defined as observed plasma concentration of Telitacicept just prior to the beginning of a dosing interval

    Time frame: up to 42 days following the last dose of Telitacicept

  4. Cav of Telitacicept

    Average concentration of Telitacicept

    Time frame: up to 42 days following the last dose of Telitacicept

  5. AUC0-t of Telitacicept

    AUC0-t is defined as area under the curve from time zero to last quantifiable concentration of Telitacicept

    Time frame: up to 42 days following the last dose of Telitacicept

  6. t1/2z of Telitacicept

    t1/2z is defined as terminal elimination half-life of Telitacicept

    Time frame: up to 42 days following the last dose of Telitacicept

  7. λz of Telitacicept

    λz is defined as terminal elimination rate constant

    Time frame: up to 42 days following the last dose of Telitacicept

Secondary outcomes

  1. SLE Responder Index 4 (SRI 4)

    SRI 4 is defined as a. SELENA-SLEDAI score reduced from baseline by at least 4 points; b. no new BILAG A or no more than 1 BILAG B compared to baseline; c. physician's global assessment (PGA) increased from baseline by less than 0.3 points.

    Time frame: Week 4, Week 8, Week 12

  2. Proportion of subjects with SELENA-SLEDAI score reduced from baseline by at least 4 points.

    The SELENA-SLEDAI is a tool for measuring the activity of systemic lupus. The total score ranges from 0-105, with a higher score representing a more significant degree of disease activity.

    Time frame: Week 4, Week 8, Week 12

  3. Change from baseline in PGA.

    The PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.

    Time frame: Week 4, Week 8, Week 12

  4. Change From Baseline in IgG

    Immunoglobulins (IgG, IgA and IgM) are proteins produced by plasma cells.

    Time frame: Week 4, Week 8, Week 12

  5. Change From Baseline in IgA

    Immunoglobulins (IgG, IgA and IgM) are proteins produced by plasma cells.

    Time frame: Week 4, Week 8, Week 12

  6. Change From Baseline in IgM

    Immunoglobulins (IgG, IgA and IgM) are proteins produced by plasma cells.

    Time frame: Week 4, Week 8, Week 12

  7. Change From Baseline in C3

    Complement (C3/C4) are proteins that are part of the immune system.

    Time frame: Week 4, Week 8, Week 12

  8. Change From Baseline in C4

    Complement (C3/C4) are proteins that are part of the immune system.

    Time frame: Week 4, Week 8, Week 12

  9. Incidence of AEs

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: up to Week 12

07

Study locations

12 sites
  • Children's Hospital of Capital Institute of Pediatrics
    Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality, China
  • Children's Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality, China
  • Henan Children's Hospital
    Zhengzhou, Henan, China
  • Hunan Children's Hospital
    Changsha, Hunan, China
  • Nanjing Children's Hospital
    Nanjing, Jiangsu, China
  • The First Hospital of Jilin University
    Changchun, Jilin, China
  • Xi'an Children's Hospital
    Xi'an, Shaanxi, China
  • Children's Hospital of Fudan University
    Shanghai, Shanghai Municipality, China
  • Chengdu Women's & Children's Central Hospital
    Chengdu, Sichuan, China
  • Children's Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • The Second Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Nov 2025, 29 months.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 29 months is close to that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2023
First posted
Jan 18, 2023
StartActual
May 25, 2023
Primary completionActual
Nov 14, 2025
CompletionActual
Nov 14, 2025
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05687526
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Jan 18, 2023
Start date
May 25, 2023
Primary completion
Nov 14, 2025
Completion
Nov 14, 2025
Last update
Mar 9, 2026

Study contacts

Hongmei Song, M.D.
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion